Ryvu Therapeutics

Ryvu Therapeutics P/B

The P/B (Price-to-Book Ratio) of Ryvu Therapeutics (RVU.WA) as of Nov 4, 2026 is 10.87. In the previous year, P/B (Price-to-Book Ratio) was 4.07 — a change of 167.27% (higher).

P/B

10.87

YoY

167.27%

Last updated:

P/B (Price-to-Book Ratio) of Ryvu Therapeutics is 2025 10.87 . P/B (Price-to-Book Ratio) of Ryvu Therapeutics was 2024 4.07 . It decreases by 167.27% higher compared to the previous year.

The Ryvu Therapeutics P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
3.05 PLN
Jan 1, 2019
4.88 PLN
Jan 1, 2020
2.61 PLN
Jan 1, 2021
3.63 PLN
Jan 1, 2022
1.70 PLN
Jan 1, 2023
2.25 PLN
Jan 1, 2024
4.07 PLN
Jan 1, 2025
10.87 PLN
The Ryvu Therapeutics P/B history
YEARP/BYoY
10.87+167.27%
4.07+80.42%
2.25+32.28%
1.70-53.03%
3.63+38.70%
2.61-46.47%
4.88+60.25%
3.05-67.54%
9.39-11.11%
10.56-16.12%
12.59-80.08%
63.21—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ryvu Therapeutics Stock analysis

What does Ryvu Therapeutics do? Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer. Ryvu Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ryvu Therapeutics stock

P/B (Price-to-Book Ratio) of Ryvu Therapeutics is 10.87 in 2025.

P/B (Price-to-Book Ratio) of Ryvu Therapeutics changed from 4.07 to 10.87, representing a 167.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Ryvu Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Ryvu Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Ryvu Therapeutics

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Ryvu Therapeutics